Investing

8 Analyst Stock Picks Under $10 for Massive Upside

Fortress Biotech Inc. (NASDAQ: FBIO) was started with a Buy rating and was given a $9 price target at Roth Capital on October 3. What should stand out here, despite having a mere $144 million market cap then, is that this analyst call predicts over 200% upside from the prior $2.97 closing price. What should also stand out is that the call was ignored entirely, because shares closed at $2.79 on Friday. The 52-week range is $2.10 to $4.66.

Immunomedics Inc. (NASDAQ: IMMU) was assumed as Buy at Jefferies, and the prior price target of $5.00 is now $5.50 (versus a $3.28 prior close). Jefferies even assigned a 55% probability of accelerated approval based on Phase 2 data in 2018. Jefferies noted that IMMU-132 has generated promising results in triple negative breast cancer. The analyst sees progress in 2016 setting the stage for a deal in the coming months ahead of the Phase 3 start by late 2016 or early 2017.

Oclaro Inc. (NASDAQ: OCLR) was started as Buy with an $11.25 price target at Jefferies on October 3. This represents upside of some 31% if the firm is right, and that target was $1.50 higher than the consensus target price of $9.75 at that time. Jefferies thinks Oclaro likely will benefit from strong demand over the next couple of years driven by multiple secular drivers around data center growth and build-outs in the United States and China. Oclaro closed out the week at $8.99, and it has a 52-week range of $2.37 to $9.34.

Petroleo Brasileiro S.A. (NYSE: PBR) was reiterated as Overweight at Morgan Stanley on October 6. While Petrobras closed out the week at $10.53, the closing price was $9.93 before the call was made. Morgan Stanley raised its price target to $13 from $10, looking for more asset sales and better conditions for the state-run oil giant. Petrobras now has a 52-week range of $2.71 to $10.61, but its consensus price target is lower at $9.59.

Other key analyst calls in stocks under $10 for the week ending October 7, 2016 were as follows:

Catalyst Pharmaceutical Inc. (NASDAQ: CPRX) was raised to Overweight from Neutral and the price target was raised to $4 from $1 (versus a $1.12 close) at Piper Jaffray.

Cytosorbents Corp. (NASDAQ: CTSO) was reiterated as Buy at Brean Capital on October 4, and its price target of $24 was more than 250% implied upside based on the prior close of $6.73. Just keep in mind that the call was largely ignored, because shares closed at $5.58 on Friday. This is based on 10 times the company’s projected 2019 EBITDA, so it has quite some time for things to develop (for better or worse) before the upside or known outcome pans out.

Neuralstem Inc. (NASDAQ: CUR) was reiterated as with a Buy rating and a price target of $4 at Brean Capital. Normally we might skip this one but the target price is effectively calling for a very rare 10-bagger return, if it turns out to be right. It is also at the very early stages, and Brean sees its $4 target based on five times the projected 2022 EBITDA. The stock closed at $0.32 on Friday, in a 52-week range of $0.19 to $1.35. If you want a more conservative target, Roth Capital has a Buy rating and a $1.20 price target.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.